Navigation Links
Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
Date:1/28/2011

ition of rights to intellectual property assets; market acceptance of our future products; government regulation of the pharmaceutical industry;  Endo's dependence on a small number of products; Endo's dependence on outside manufacturers for the manufacture of a majority of its products;  Endo's dependence on third parties to supply raw materials and to provide services for certain core aspects of its business; new regulatory action or lawsuits relating to Endo's or Qualitest's use of narcotics in many of its core products; Endo's and Qualitest's exposure to product liability claims, market withdrawals and product recalls and the possibility that Endo may not be able to adequately insure itself; the successful efforts of manufacturers of branded pharmaceuticals to use litigation and legislative and regulatory efforts to limit the use of generics and certain other products; Endo's ability to successfully implement its acquisition and in-licensing strategy; regulatory or other limits on the availability of controlled substances that constitute the active ingredients of some of its products and products in development; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by third parties or the government, and the performance of indemnitors with respect to claims for which we have been indemnified; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of its total revenues; a determination by a regulatory agency that Endo is engaging or has engaged in inappropriate sales or marketing activities, including promoting the "off-label" use of its products, the risk that demand for and acceptance of our products or services may be reduced; the risk of changes in governmental regulations; the impact of economic conditions; the impact of competition and pricing and other risks and uncertainties, including those detailed from time to
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government
3. JHP Pharmaceuticals and Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
4. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
5. Amylin Pharmaceuticals Reports 2010 Financial Results
6. Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
7. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
8. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
9. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
10. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
11. Amylin Pharmaceuticals to Webcast Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... July 12, 2011 Particle Sciences ... Systems, a leading provider of pre-clinical pharmacokinetic services, ... together to provide their clients with enhanced drug ... the dosage form development scheme.   ...
... Helping Virologists Keep,Up- to- Date ... Elsevier ( http://www.elsevier.com ) has,announced the publication of the first ... in its prestigious Current Opinion,series, publishing six issues a year. ... filtered approach to the ever-expanding wealth of research,published on viruses and ...
Cached Medicine Technology:Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services 2Elsevier Launches Current Opinion in Virology 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... my mom’s stroke, she loss the use of her right side. ... his left side. Eating became a difficult task for them so ... enjoy eating again,” said an inventor, from Fayetteville, N.C. As a ... (P C H PLATE). , The PATRICIA CAROL HALL PLATE (P ... individuals who suffer from stroke, experience tremors or loss of movement. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... progression, mouse study suggests , , MONDAY, April 14 (HealthDay ... cholesterol and one is an anti-inflammatory -- may be ... presented at the American Association for Cancer Research annual ... and the statin Lipitor, when used together or alone, ...
... Kimmel Cancer Center at Thomas Jefferson University in ... blood pressure medications might help prevent the spread ... laboratory that one type of pressure-lowering drug called ... growth and causes cell death. , In earlier ...
... Real-Time In Vivo Data via Quantitative ... ... Inc., a leader,in fluorescence in vivo imaging, today announced the commercial ... is based on VisEn,s,proprietary Fluorescence Molecular Tomography (FMT(TM)) technology,platform, and combined ...
... 14 HealthFusion, a,national clearinghouse for ... center operation customer satisfaction excellence under ... Center Program(SM). This distinction,acknowledges a strong ... to provide "An Outstanding Customer Service ...
... As the first of the,nation,s 78 million baby boomers ... health care work force that is too small and ... new report from the Institute of,Medicine. The report calls ... providers -- not just specialists -- in the basics ...
... Denise Kehoe has joined,medication therapy management (MTM) company ... new role, she will manage and oversee the,expansion ... the country., Kehoe brings more than 15 ... PharmMD. She recently served as national strategic,executive of ...
Cached Medicine News:Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 2Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis 2Health News:PharmMD Announces Denise Kehoe as Vice President of Business Development 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
... bacterial growth system, combines orbital shaking, ... format for bacterial growth. It is ... HT-Prep™ Automatic DNA Extractor. The uniquely ... traditional floor shakers. Plate-holding cassettes allow ...
Medicine Products: